CAIRO:– In line with Egypt's drive to confront population growth and boost family planning, PHARCO will launch a new company, specialized in the manufacturing of women's medicines, i.e. birth control pills and healthcare hormones for women of all ages.
The new state-of-the-art company, the first of its kind in Egypt, will mark a milestone in PHARCO's history of looking after the Egyptian family and society as a whole.
“The group is launching a new company specialized in the production of medicines for women driven by our commitment to this nation and to contribute to the mitigation of the negative impacts of population growth and to rein in the depletion of Egypt's economic resources," said Dr. Sherine Helmy, Deputy Chairman & Managing Director of PHARCO Group.
Last year, the Ministry of Health and Population launched "Operation Lifeline", a strategy to reduce the birthrate to 2.4, saving the government up to EGP 200 billion (around $ 11.2 billion) by 2030.
The launch of the new company to produce medicines for women comes within the framework of a strategy, initiated by President Abdel Fattah El Sisi, for the advancement of Egyptian women, as one half of our society and a pillar for state development plans.
"We have faith in the importance of women in our society and their key role in the advancement of our nation socially, economically and politically. Therefore, we will launch the first company in Egypt with state-of-the-art technology to produce hormone treatments and other drugs of the world's top quality for the best interest of women and the Egyptian society," Dr. Helmy added.
It's noteworthy that PHARCO Group was established 30 years ago by the group's Chairman Dr. Hassan Abbas Helmy, who has founded a successful group of healthcare producers in Egypt and the Middle East.
-Ends-© Press Release 2018
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.